Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study compares two standard methods for cleaning the surface of wounds on the feet of patients with diabetes mellitus. The question being asked is whether inflammation of the wound affects the ability of one or both of the methods to work.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Active Comparator | Santyl |
|
| B | Active Comparator | Tegaderm Hydrogel |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Santyl | Drug | Apply one 24-hr period sufficient to cover the wound. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Wound Appearance | Weekly wound appearance as assessed by BWAT-m scores. BWAT-m scores used to determine primary efficacy consist of 8 subscales, each grade an aspect of wound status on a 1-5 scale; 1=normal intact skin; 5=least desirable. Total score=8-40. Subscales: Edges, Undermining, Necrotic Tissue Type, Necrotic Tissue Amount, Exudate Type, Exudate Amount, Skin Color Surrounding Wound, and Granulation Tissue. | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change in Wound Area | 28 days |
Not provided
Inclusion Criteria:
The informed consent document must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent document must be signed and dated by the individual who consents the subject before conducting the screening visit. A photocopy of the signed informed consent document must be provided to the subject, and the original signed document placed in the subject's chart.
Of either sex, aged 18 years or older.
A diagnosis of Diabetes Mellitus, Type I or II, requiring medication to control blood glucose levels.
A qualifying ulcer, defined as follows:
Requires debridement of the wound bed
Is sufficiently moist to allow collection of wound fluid using a filter paper disc
Adequate arterial blood flow evidenced by ankle brachial index (ABI) of ≥ 0.7 and ≤ 1.1; if the ABI is greater than 1.1, then toe pressure of >50 mmHg.
Subject must be willing to use the Darco shoe off-loading device and insole, or a comparable device, as indicated.
Subject able to follow instructions, particularly regarding the application of test articles and dressings at home. Able to apply the test articles, or has a caregiver available to apply the test articles according to the protocol.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Herbert B Slade, MD | Healthpoint | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Richard C. Galperin, DPM | Dallas | Texas | 75224 | United States |
Not provided
Adults aged 18 years and older, with Type I or II diabetes mellitus and at least one inflamed diabetic foot ulcer
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Collagenase Santyl Ointment | Santyl Santyl : Applied once every 24-hr period sufficient to cover the wound. |
| FG001 | Control | Tegaderm Hydrogel Tegaderm Hydrogel : Applied once every 24-hr period sufficient to cover the wound. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Collagenase Santyl Ointment | Santyl Santyl : Applied once every 24-hr period sufficient to cover the wound. |
| BG001 | Control | Tegaderm Hydrogel Tegaderm Hydrogel : Applied once every 24-hr period sufficient to cover the wound. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Wound Appearance | Weekly wound appearance as assessed by BWAT-m scores. BWAT-m scores used to determine primary efficacy consist of 8 subscales, each grade an aspect of wound status on a 1-5 scale; 1=normal intact skin; 5=least desirable. Total score=8-40. Subscales: Edges, Undermining, Necrotic Tissue Type, Necrotic Tissue Amount, Exudate Type, Exudate Amount, Skin Color Surrounding Wound, and Granulation Tissue. | 12 subjects initially for this exploratory study. 17 subjects enrolled to ensure 12 evaluable. Intent-to-treat used for primary inference. Missing values imputed by method of population mean (BWAT-m) and last observation carried forward (wound area). | Posted | Mean | Standard Deviation | units on a scale | 28 days |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Collagenase Santyl Ointment | Santyl Santyl : Applied once every 24-hr period sufficient to cover the wound. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pneumonia | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Oedema Peripheral | Gastrointestinal disorders | MedDRA (13.1) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jaime E. Dickerson, PhD; Sr. Director Clinical Affairs | Healthpoint, Ltd. | 817-302-3914 | jaime.dickerson@healthpoint.com |
Not provided
| ID | Term |
|---|---|
| D017719 | Diabetic Foot |
| ID | Term |
|---|---|
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D016523 | Foot Ulcer |
Not provided
Not provided
| ID | Term |
|---|---|
| D017364 | Collagenases |
| ID | Term |
|---|---|
| D008666 | Metalloendopeptidases |
| D010450 | Endopeptidases |
| D010447 | Peptide Hydrolases |
| D006867 | Hydrolases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tegaderm Hydrogel |
| Drug |
Apply once 24-hr period sufficient to cover the wound. |
|
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Control | Tegaderm Hydrogel Tegaderm Hydrogel : Applied once every 24-hr period sufficient to cover the wound. |
|
|
| Secondary | Percent Change in Wound Area | Intent-to-Treat | Posted | Mean | Standard Deviation | percentage change from baseline area | 28 days |
|
|
|
| 1 |
| 9 |
| 2 |
| 9 |
| EG001 | Control | Tegaderm Hydrogel Tegaderm Hydrogel : Applied once every 24-hr period sufficient to cover the wound. | 1 | 8 | 3 | 8 |
| Cellulitis | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
|
| Diabetic Ulcer | Skin and subcutaneous tissue disorders | MedDRA (13.1) | Systematic Assessment |
|
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release.
| D007871 |
| Leg Ulcer |
| D012883 | Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
| D003929 | Diabetic Neuropathies |
| D004798 |
| Enzymes |
| D045762 | Enzymes and Coenzymes |
| D045726 | Metalloproteases |